Hemlibra (Emicizumab)

Hemlibra is indicated for prophylactic treatment of hemophilia A, with or without factor VIII inhibitors, to reduce the frequency of bleeding episodes.

• Routine prophylaxis in patients of any age with hemophilia A, regardless of inhibitor status.
• Prevention of spontaneous joint and muscle bleeds in individuals with severe hemophilia A.
• Management of patients who have developed inhibitors to factor VIII, offering an alternative to bypassing agents.
• Use as part of a comprehensive hemophilia care plan, including physiotherapy and monitoring of joint health.
• May be considered for patients who prefer less frequent dosing compared with traditional factor replacement.

Clinical studies have identified a range of adverse events associated with emicizumab; they are categorized by frequency and severity.

Common

• Injection‑site reactions such as erythema, swelling, or pain.
• Headache or mild dizziness.
• Upper respiratory tract infection symptoms.
• Nausea or transient gastrointestinal discomfort.

Serious

• Thrombotic microangiopathy, especially with concomitant activated prothrombin complex concentrate.
• Severe allergic reactions, including anaphylaxis.

When prescribing emicizumab, clinicians should evaluate individual risk factors and monitor patients for specific safety concerns.

• Assess for a history of thrombotic events before initiating therapy.
• Avoid concurrent use of activated prothrombin complex concentrate unless medically necessary.
• Monitor for signs of thrombotic microangiopathy during treatment.
• Counsel patients on proper subcutaneous injection technique to reduce local reactions.
• Evaluate pregnancy status; the safety profile in pregnancy is not established.
• Adjust dosing in patients with severe renal or hepatic impairment only under specialist guidance.
• Report any unexpected bleeding or clotting episodes to a hemophilia treatment center.

Emicizumab may interact with other agents that affect coagulation; awareness of these interactions helps maintain safety.

Avoid

• Activated prothrombin complex concentrate (aPCC) – concurrent use can precipitate thrombotic microangiopathy.
• High‑dose factor VIII concentrates in patients receiving emicizumab – may increase thrombotic risk.

Use with caution

• Antifibrinolytic agents such as tranexamic acid – monitor for clotting complications.
• Immunosuppressive therapies – may alter the immunogenicity profile of emicizumab.
• Other monoclonal antibodies – assess for additive immunologic effects.